Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 18,425 Shares of Stock

Key Points

• Insider sale: Julie Green sold 18,425 Invivyd shares for approximately $15,477, reducing her holdings by 9.83%. The sale was disclosed as covering tax-withholding obligations from vested equity awards, alongside a separate sale of 22,355 shares the previous day.
• Stock performance and results: Invivyd shares rose 17.2% to $0.87 during Tuesday trading. The company reported a quarterly loss of $0.14 per share, missing estimates by $0.03, while revenue of $14.29 million was slightly below expectations.
• Analyst view remains mixed: The stock has a consensus “Hold” rating and an $8.00 price target, with three Buy, two Hold, and one Sell ratings. Institutional investors and hedge funds own 70.36% of the company.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Julie Green sold 18,425 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $15,477.00. Following the transaction, the insider owned 168,937 shares of the company's stock, valued at approximately $141,907.08. This trade represents a 9.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Monday, August 17th, Julie Green sold 22,355 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60.

Invivyd Trading Up 17.2%

Shares of NASDAQ IVVD traded up $0.13 during midday trading on Tuesday, reaching $0.87. The company's stock had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a one year low of $0.48 and a one year high of $3.07. The company has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The company has a 50 day moving average price of $0.77 and a 200 day moving average price of $1.23.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The business had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Research analysts anticipate that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating on shares of Invivyd in a research note on Tuesday. BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen downgraded Invivyd from a "hold" rating to a "strong sell" rating in a report on Saturday, May 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Invivyd in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $8.00.

Institutional Trading of Invivyd

Several large investors have recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC purchased a new stake in shares of Invivyd in the second quarter valued at $84,000. Bank of America Corp DE acquired a new stake in shares of Invivyd in the second quarter worth $311,000. Jupiter Topco LLC purchased a new position in shares of Invivyd during the second quarter valued at $30,048,000. ADAR1 Capital Management LLC purchased a new position in shares of Invivyd during the second quarter valued at $3,322,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Invivyd during the second quarter valued at $52,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd News Roundup

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source